Fludarabin monoterápiával kezelt krónikus lymphoid leukaemiás betegeink hosszú távú követése során szerzett megfigyeléseink.

F. Varga, D. Lehoczky, J. Demeter

Research output: Article


Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease. In our study the clinical response and survival of 9 patients with a mean follow-up time of 28 months after treatment with fludarabine as a single agent for CLL has been evaluated. Seven patients were previously treated. Partial remission was achieved in 8 patients. No complete remission was seen. The cytoreductive activity of fludarabine was excellent in all the 9 patients. The median time to progression was 13.5 months. The median survival time from entering the trial was 27.9 months. Our patients tolerated the fludarabine treatment extremely well. Although fludarabine has been established as the most active single agent in CLL, most patients will have recurrent disease. 7/9 patients relapsed in our study, and they were given further chemotherapy. Grade 4 hematologic toxicity was observed in 2 patients. During the fludarabine treatment the frequency of infections decreased, but in the following 12 months increased again. Three fludarabine-treated patients developed high-grade non-Hodgkin lymphoma. It is concluded that fludarabine is a highly useful agent in CLL.

Original languageHungarian
Pages (from-to)1731-1735
Number of pages5
JournalOrvosi hetilap
Issue number31
Publication statusPublished - aug. 1 1999


ASJC Scopus subject areas

  • Medicine(all)

Cite this